Medicinal composition containing strontium salt

Abstract

The invention relates to a medicinal composition containing strontium salts and vitamin D derivatives. Mixed with auxiliary materials acceptable on pharmacy, the medicinal composition of the invention can be prepared into oral formulations such as particulate granules, common tablets, chewable tablets, dispersible tablets, orally disintegrating tablets, effervescent tablets, buccal tablets, capsules, softgels, sustained release tablets, sustained release capsules, oral solutions, syrups, etc., and can be used to prevent and treat various primary or secondary osteoporosis.

Description

technical field

[0001] The invention relates to a pharmaceutical composition containing strontium salt, which belongs to the technical field of medicine. Background technique

[0002] Osteoporosis is a systemic bone disease characterized by low bone mass and destruction of bone microarchitecture, resulting in increased bone fragility and susceptibility to fracture. A common cause of osteoporosis in women is the rapid decline in estrogen levels after menopause and the acceleration of bone metabolism, resulting in an imbalance between bone formation and bone resorption. Most of the drugs used to treat osteoporosis are based on the mechanism of anti-bone resorption, which reduces excessive bone metabolism and maintains normal bone mass and bone strength, thereby reducing the incidence of fractures in postmenopausal women. The effect of metabolic drugs on bone formation is greater than that on bone resorption, thereby increasing bone remodeling, ultimately leading to increased ...

Examples

Embodiment 1

[0014] Strontium ranelate, alfacalcidol dry suspension granules

[0015] prescription:

[0016]

[0017] Preparation:

[0018] Add tartrazine into PVP-k30 aqueous solution, stir to dissolve and set aside.

[0019] Pass the prescription amount of strontium ranelate, alfacalcidol, sucrose, L-HPC, and strawberry essence through an 80-mesh sieve, mix well, add 2% PVP-k30 aqueous solution to make a soft material, and granulate with a 24-mesh sieve , dried, granulated, subpackaged.

Embodiment 2

[0021] Strontium Succinate, Alfacalcidol Dry Suspension Granules

[0022] prescription:

[0023]

[0024] Preparation:

[0025] Add carmine into the PVP-k30 aqueous solution, stir and dissolve for later use.

[0026] Pass the prescription amount of strontium succinate, alfacalcidol, sucrose, L-HPC, and strawberry essence through 80-mesh sieve respectively, after mixing evenly, add 2% PVP-k30 aqueous solution to make soft material, and granulate with 24-mesh sieve. Dried, granulated, subpackaged.

Embodiment 3

[0028] Strontium ranelate, maxacalcitol dry suspension granules

[0029] prescription:

[0030]

[0031] Preparation:

[0032] Add carmine into the PVP-k30 aqueous solution, stir and dissolve for later use.

[0033] Pass the prescription amount of strontium ranelate, maxacalcitol, sucrose, L-HPC, and sweet orange flavor through a 80-mesh sieve, mix well, add 5% PVP-k30 aqueous solution to make a soft material, and granulate with a 24-mesh sieve , dried, granulated, subpackaged.

technical field

[0001] The invention relates to a pharmaceutical composition containing strontium salt, which belongs to the technical field of medicine. Background technique

[0002] Osteoporosis is a systemic bone disease characterized by low bone mass and destruction of bone microarchitecture, resulting in increased bone fragility and susceptibility to fracture. A common cause of osteoporosis in women is the rapid decline in estrogen levels after menopause and the acceleration of bone metabolism, resulting in an imbalance between bone formation and bone resorption. Most of the drugs used to treat osteoporosis are based on the mechanism of anti-bone resorption, which reduces excessive bone metabolism and maintains normal bone mass and bone strength, thereby reducing the incidence of fractures in postmenopausal women. The effect of metabolic drugs on bone formation is greater than that on bone resorption, thereby increasing bone remodeling, ultimately leading to increased ...

Examples

Embodiment 1

[0014] Strontium ranelate, alfacalcidol dry suspension granules

[0015] prescription:

[0016]

[0017] Preparation:

[0018] Add tartrazine into PVP-k30 aqueous solution, stir to dissolve and set aside.

[0019] Pass the prescription amount of strontium ranelate, alfacalcidol, sucrose, L-HPC, and strawberry essence through an 80-mesh sieve, mix well, add 2% PVP-k30 aqueous solution to make a soft material, and granulate with a 24-mesh sieve , dried, granulated, subpackaged.

Embodiment 2

[0021] Strontium Succinate, Alfacalcidol Dry Suspension Granules

[0022] prescription:

[0023]

[0024] Preparation:

[0025] Add carmine into the PVP-k30 aqueous solution, stir and dissolve for later use.

[0026] Pass the prescription amount of strontium succinate, alfacalcidol, sucrose, L-HPC, and strawberry essence through 80-mesh sieve respectively, after mixing evenly, add 2% PVP-k30 aqueous solution to make soft material, and granulate with 24-mesh sieve. Dried, granulated, subpackaged.

Embodiment 3

[0028] Strontium ranelate, maxacalcitol dry suspension granules

[0029] prescription:

[0030]

[0031] Preparation:

[0032] Add carmine into the PVP-k30 aqueous solution, stir and dissolve for later use.

[0033] Pass the prescription amount of strontium ranelate, maxacalcitol, sucrose, L-HPC, and sweet orange flavor through a 80-mesh sieve, mix well, add 5% PVP-k30 aqueous solution to make a soft material, and granulate with a 24-mesh sieve , dried, granulated, subpackaged.

Images